Loading
In ADCC, an antibody flags a cell, and NK cells recognise the flag and kill it.
ADCC, antibody-dependent cellular cytotoxicity, is the process in which an antibody flags a cell and NK cells recognise the flag and kill it. It is mediated by the interaction between the antibody Fc region and FcγRIIIa (CD16) on the NK cell, and it can be enhanced by afucosylating the antibody, as in obinutuzumab, margetuximab and belantamab. ADCC contributes to the activity of trastuzumab, rituximab and cetuximab, and the mechanism belongs to the Monoclonal antibodies technology entry. Drug records that cite it include Margetuximab, Zolbetuximab, Obinutuzumab, Rituximab, Tafasitamab, Daratumumab, Mogamulizumab, Elotuzumab and Dinutuximab (ch14.18) / dinutuximab beta, and it is referenced by the Gastric & gastro-oesophageal junction cancer and Neuroblastoma (paediatric) entries.
Showing the technology this term belongs to: Monoclonal antibodies.
Shares NK cell, Margetuximab, Mogamulizumab, Antibody.
Shares Tafasitamab, Obinutuzumab, Rituximab.
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric), Monoclonal antibodies.
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).